We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Zejula

News List

Tesaro secures EU approval in specific ovarian cancer population pharmafile
November 24, 2017
The European Commission has granted Tesaro’s Zejula (niraparib) marketing approval in Europe, it has emerged.
STA Pharmaceutical signs deal with Tesaro for zejula pharmaceutical-technology
July 27, 2017
STA Pharmaceutical, a US subsidiary of China-based company WuXi AppTec, has signed a new supply agreement with oncology-focused biopharmaceutical company Tesaro for certain starting and intermediate materials for zejula (niraparib).
FDA Approves Maintenance Treatment for Recurrent Epithelial Ovarian, Fallopian Tube or Primary Perit americanpharmaceuticalreview
March 29, 2017
The U.S. Food and Drug Administration has approved Zejula for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk in response to plati
FDA Approves Zejula drugs
March 28, 2017
Tesaro Announces FDA Approval of Zejula (niraparib) for Women with Recurrent Ovarian Cancer.

Previous page 1 2 Next page